Abiomed (Ticker: ABMD) peaked around June 2018 and retested the highs again in September 2018. Watch the divergence between the money flow and the stock price as it tested its old highs. It was clearly a sign that the stock has peaked. 

Fundamentally, the stock price was over inflated with exaggerated PE of almost 200. PROBLEM was that there was not enough earning growth to justify those multiples.

SELLING POINTS: Weakness as demonstrated by Momentum indicators, Breakdown of 50 day and 200 day moving average, and failure to go past them on retests, was a clear sign that the stock was destined for a failure. 

KEEP CHECKING US OUT AS WE KEEP UPDATING HERE WITH NEW POSTS/ IDEAS TO UPDATE ON THE MARKET TRENDS.